2016 IPO

CRISPR Therapeutics Stock

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.

Sign up today and learn more about CRISPR Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About CRISPR Therapeutics Stock

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

Funding History

April 2014$25.0M
April 2015$64.0M
June 2016$38.0M

Management

Scientific Founders

Daniel Anderson

Scientific Founders

Emmanuelle Charpentier

Founder & CFO

Shaun Foy

Founder & Chief Executive Officer

Rodger Novak

Scientific Founders

Craig Mello

Chief Scientific Officer

Bill Lundberg

Scientific Founders

Chad Cowan

Scientific Founders

Matthew Porteus

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo